Patent · US Active

Oxprenolol compositions for treating cancer

US11433036B2 · kind B2 · utility

0Cited by

3References

20Claims

0Family size

Assignee

ACTIMED THERAPEUTICS LIMITED · GB

Inventors

Andrew J. S. Coats · Melbourne, AU
Stefan Anker · Berlin, DE
Jochen Springer · Falkensee, DE

Key dates

Filing date	Oct 7, 2020
Grant date	Sep 6, 2022
Priority date	—
Expiry date	Oct 7, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.